FULC Earnings

FULC reported its FY2025Q3 earnings on 2025-10-29, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.31, surpassing the expected -0.29 by -6.9% . The stock experienced a -6.4% price change on the earnings day and a -9.8% change over the next five days, reflecting market reactions to the results.

Following FULC's FY2025Q3 earnings announcement on 2025-10-29, the stock price moved by -6.40% on the day of the release. Over the subsequent five days, it saw a -9.80% change. Historically, FULC's stock price tends to shift by an average of -8.88% in the 10 days leading up to earnings and +0.04% in the 10 days following, providing insight into potential market.

For , analysts estimate FULC’s annual revenue to reach , while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Go Up by 27.21% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between FULC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Go Up by 27.21% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FULC's stock price typically moves by -8.88% in the 10 days before its earnings and +0.04% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of .

The earnings call summary and Q&A session reveal a balanced sentiment. While there are positive developments such as the anticipation of the 20mg dose outperforming the 12mg dose and the urgency to address unmet needs, there are also uncertainties like the lack of specific guidance on FDA safety data requirements and unclear management responses. No clear catalysts like new partnerships or financial metrics were discussed, resulting in a neutral outlook for stock price movement.